Radiation-Induced Fibrosis Treatment Market

Radiation-Induced Fibrosis Treatment Market Size, Market Forecast and Outlook By FMI

The radiation-induced fibrosis treatment market was valued at USD 79.0 million in 2025. the market is set to reach USD 83.9 million by 2026-end and grow at a CAGR of 6.2% between 2026-2036 to reach USD 153.1 million by 2036. Pharmaceuticals will dominate with a 55.0% share.

Summary of the Radiation-Induced Fibrosis Treatment Market

• Demand and Growth Drivers
  • Rising cancer survivorship rates are increasing the patient population experiencing radiation-induced fibrosis, Creating sustained demand for treatment interventions.
  • Regulatory approvals for anti-fibrotic pharmaceutical agents are expanding the treatment options available for post-radiation tissue fibrosis management.
  • Clinical research into combination therapy approaches is creating new treatment protocols that expand pharmaceutical and device utilization per patient.
• Product and Segment View
  • Pharmaceuticals lead the product segment at 55.0%, reflecting the role of anti-fibrotic drugs and supportive pharmacotherapy as first-line treatment for radiation-induced fibrosis.
  • Hyperbaric oxygen therapy leads the therapy type segment, driven by established clinical evidence for tissue oxygenation and fibrosis symptom management.
  • Oral administration leads the route of administration segment, reflecting the dominance of tablet-based long-term treatment protocols for fibrosis management.
• Geography and Competitive Outlook
  • The USA leads with a 6.5% CAGR, reflecting advanced oncology care infrastructure and reimbursement coverage for fibrosis treatment interventions.
  • South Korea at 6.4% CAGR sustains demand through healthcare modernization and growing investment in cancer survivorship care programs.
  • Companies with approved anti-fibrotic therapeutics and established oncology care distribution are positioned for prescription volume growth.
• Analyst Opinion
  • 'Companies with approved anti-fibrotic therapeutics and clinical data supporting efficacy in radiation-induced fibrosis are positioned to benefit from growing cancer survivorship and expanding treatment awareness.'
  • The market is evolving from symptom management toward disease-modifying treatment approaches targeting fibrotic tissue remodeling.
  • Oncologist awareness of radiation-induced fibrosis as a treatable condition is increasing, Expanding diagnosis rates and treatment initiation.
  • Demand is supported by the growing global cancer survivorship population and increasing emphasis on quality of life in post-treatment care.

Key Takeaways, Market Size, And Forecast

• The radiation-induced fibrosis treatment market was valued at USD 79.0 million in 2025.
• By 2036, The Radiation-Induced Fibrosis Treatment Market is expected to be worth USD 153.1 million.
• From 2026 to 2036, The market is projected to expand at a CAGR of 6.2%.
• The market is projected to create an incremental opportunity of USD 69.2 million between 2026 and 2036.
• In 2026, Pharmaceuticals is expected to account for 55% of the product segment, Driven by demand for established clinical protocols and pharmacotherapy as first-line management for post-radiation tissue fibrosis.
• USA (6.5%) and South Korea (6.4%) are two of the fastest growing markets in the world.

Radiation-Induced Fibrosis Treatment Market Definition

The radiation-induced fibrosis treatment market encompasses pharmaceutical products, Medical devices, and therapeutic interventions used for the management and treatment of tissue fibrosis resulting from radiation therapy in cancer patients. Market scope includes anti-fibrotic drugs, Hyperbaric oxygen therapy, Physical therapy modalities, and combination treatment approaches.

Radiation-Induced Fibrosis Treatment Market Inclusions

Market scope includes all commercially traded radiation-induced fibrosis treatments categorized by product (pharmaceuticals, Medical devices, Combination therapy), Therapy type (hyperbaric oxygen, Pharmacotherapy, Physical therapy), Route of administration, Indication, end user, and distribution channel. Revenue sizing covers the 2026 to 2036 forecast period.

Radiation-Induced Fibrosis Treatment Market Exclusions

The scope does not include radiation therapy equipment, Cancer chemotherapy drugs, or general wound care products not specifically indicated for radiation-induced fibrosis.

Radiation-Induced Fibrosis Treatment Market Research Methodology

• Primary Research: FMI analysts conducted interviews with manufacturers, Distributors, Procurement specialists, and end-use application experts in key markets.
• Desk Research: Combined data from industry associations, regulatory filings, Certification bodies, and manufacturer disclosures.
• Market Sizing and Forecasting: Bottom-up aggregation across product, Therapy type, Route of administration, application, end user, distribution channel, technology segments, with regional adoption curves and cross-referencing against publicly available industry data.
• Data Validation: Cross-checked quarterly against global production data, Trade statistics, and manufacturer-reported figures.

Why is the Radiation-Induced Fibrosis Treatment Market Growing?

• As cancer survivorship rates increase, the patient population requiring treatment for radiation-induced tissue fibrosis is increasing.
• Increasing regulatory approvals of anti-fibrotic agents are leading to more treatment options and fuelling physician prescribing activity.
• The USA is experiencing the highest growth at a CAGR of 6.5% due to its advanced oncology care infrastructure and availability of reimbursement for fibrosis interventions.

The radiation-induced fibrosis treatment market is growing due to the increasing cancer survivorship and rising clinical awareness regarding the post-radiation fibrosis as a treatable condition. Radiation-induced fibrosis affects a large proportion of cancer patients WHO receive radiation therapy, Resulting in tissue stiffening, Pain, and functional impairment that impacts quality of life. growth is fueled by an expanding patient population along with an expanding array of pharmacologic and device-based treatment options.

Pharmaceuticals are leading with 55.0% and this shows the significance of the anti-fibrotic drugs as the first line of treatment. Hyperbaric oxygen therapy is the best non-drug intervention and has clinical evidence for benefits for tissue oxygenation. the market structure is changing with pharmaceutical companies investing in anti-fibrotic clinical programs for radiation indications.

Market Segmentation Analysis

• Pharmaceuticals leads the product segment with 55% market share, reflecting established supply and end-use preference.
• Hyperbaric Oxygen Therapy holds the leading position in the therapy type category.
• Oral accounts for the largest share in the route of administration segment.

The radiation-induced fibrosis treatment market is segmented by product, Therapy type, Route of administration, application, end user, distribution channel, technology. Each segment reflects distinct procurement criteria, end-use requirements, and pricing structures.

Insights into the Product Segment

Pharmaceuticals holds the leading position in the product segment at 55%. Demand is shaped by established end-use compatibility, Supply chain availability, and cost competitiveness relative to alternative options.

Other product categories include Anti Fibrotic Drugs, Pirfenidone Based Therapy, Nintedanib Based Therapy, Each serving specific application requirements and reflecting technical specification diversity across end-use industries.

Insights into the Therapy Type Segment

Hyperbaric Oxygen Therapy holds the leading position in the therapy type segment. Demand is shaped by established end-use compatibility, Supply chain availability, and cost competitiveness relative to alternative options.

Other therapy type categories include Systemic Oxygen Treatment, Tissue Oxygenation, Wound Healing Support, Each serving specific application requirements and reflecting technical specification diversity across end-use industries.

Radiation-Induced Fibrosis Treatment Market Drivers, Restraints, and Opportunities

• With the rising population of cancer survivors, the patient population suffering from radiation-induced fibrosis is increasing, Creating an increasing demand for treatment interventions.
• Diagnosis rates and treatment initiation are limited by physician awareness of treatment options and variable reimbursement coverage.
• The expansion of pharmaceutical pipelines targeting fibrotic tissue remodeling is broadening the therapeutic arsenal beyond symptom management.

The market for radiation-induced fibrosis treatment is gradually developing, driven by regulatory factors, Cost structure constraints and new application opportunities. adoption rates may vary by segment and geography and price sensitivity for end-use applications.

Cancer Survivorship Growth

Better cancer treatment outcomes are extending survivorship and thus the population of patients with radiation-induced fibrosis is increasing. the pool of patients WHO need fibrosis management continues to grow with each additional year of survivorship.

Awareness and Reimbursement Barriers

The level of physician awareness of options to treat radiation induced fibrosis varies between healthcare systems. Limited initiation of treatment in cost-constrained settings is subject to variable reimbursement coverage.

Pipeline Development

The pharmaceutical industry is developing anti-fibrotic drug candidates to target the biological mechanisms of radiation-induced tissue fibrosis. Disease-modifying agents offer a significant opportunity for growth of the market if clinical development programmes are successful.

Analysis of Radiation-Induced Fibrosis Treatment Market By Key Countries

Country	CAGR
USA	6.5%
South Korea	6.4%
Japan	6.2%
UK	6%
EU	5.9%

• USA to lead with 6.5% CAGR, Owing to strong procurement networks.
• Strong demand as technology-LED adoption: South Korea at 6.4%
• Japan (6.2%) and UK (6%) continue to grow on the back of end-use industry growth.

The global radiation-induced fibrosis treatment market is expected to grow at a rate of 6.2% per year from 2026 to 2036. the study covers more than 30 countries, and the main markets are listed below.

Demand Outlook for Radiation-Induced Fibrosis Treatment Market in USA

USA is projected to grow at a rate of 6.5% through 2036, reflecting established procurement networks, regulatory compliance investment, and strong end-use demand. Demand is supported by compliance-driven procurement, established distribution networks, and premium product demand.

• Compliance-LED procurement is sustaining demand for products meeting regulatory specifications.
• Established distribution networks support efficient supply chain coverage across end-use sectors.
• Premium product demand is creating value-added procurement channels alongside volume purchasing.

Future Outlook for Radiation-Induced Fibrosis Treatment Market in South Korea

South Korea is projected to grow at a rate of 6.4% through 2036, reflecting technology-LED adoption, manufacturing sector modernization, and export-oriented production capabilities. Demand is supported by manufacturing sector investment, technology adoption, and export-oriented capabilities.

• Technology-LED adoption is driving procurement modernization across industrial applications.
• Manufacturing sector investment supports domestic demand and export competitiveness.
• Regulatory development is raising product specification requirements across categories.

Opportunity Analysis of Radiation-Induced Fibrosis Treatment Market in Japan

Japan is projected to grow at a rate of 6.2% through 2036, reflecting advanced manufacturing capabilities, quality-driven procurement standards, and technology adoption. Demand is supported by quality-driven procurement standards, advanced manufacturing, and technology adoption.

• Quality-driven procurement standards sustain demand for high-specification products.
• Advanced manufacturing capabilities support domestic production and technology adoption.
• Established industry infrastructure enables efficient distribution across end-use sectors.

In-depth Analysis of Radiation-Induced Fibrosis Treatment Market in UK

UK is projected to grow at a rate of 6% through 2036, reflecting regulatory alignment with quality standards and established distribution infrastructure. Demand is supported by regulatory alignment, established distribution channels, and quality-driven procurement.

• Regulatory standards alignment is shaping product specifications and procurement criteria.
• Established distribution infrastructure supports efficient market coverage across the region.
• Premium segment demand is creating opportunities for value-added product positioning.

Sales Analysis of Radiation-Induced Fibrosis Treatment Market in Europe

Europe is projected to grow at a rate of 5.9% through 2036, reflecting EU regulatory frameworks, sustainability mandates, and advanced manufacturing infrastructure. Demand is supported by EU-wide regulatory harmonization, sustainability mandates, and advanced manufacturing infrastructure.

• EU regulatory frameworks are creating compliance-LED demand across member states.
• Sustainability mandates are accelerating adoption of compliant product specifications.
• Advanced manufacturing infrastructure supports efficient production and distribution.

Competitive Landscape and Strategic Positioning

• Merck KGaA holds a leading position owing to established manufacturing infrastructure, Broad product portfolio, and strong end-use customer relationships.
• Sanofi S.A. and Bristol-Myers Squibb maintain competitive positions through product breadth and regional distribution capabilities.
• Smaller and emerging players are focusing on specialized applications and niche segments to build market position.

Merck KGaA is a leading participant owing to broad manufacturing capacity and established relationships with end-use customers across multiple geographies. Sanofi S.A. competes through product portfolio breadth and distribution reach.

Bristol-Myers Squibb and Galecto, Inc. maintain competitive positions in specific product categories and regional markets. Barriers to entry include manufacturing scale requirements, regulatory certification timelines, and established procurement relationships.

Strategic priorities include cost optimization, Geographic expansion, product specification upgrades, and alignment with regulatory compliance timelines.

Key Companies in the Radiation-Induced Fibrosis Treatment Market

Key global companies leading the radiation-induced fibrosis treatment market include:

• Merck KGaA, Sanofi S.A., Bristol-Myers Squibb hold leading positions through established infrastructure and strong customer relationships.
• Galecto, Inc. and Trevi Therapeutics, Inc. maintain competitive positions through regional expertise and product specialization.

Competitive Benchmarking: Radiation-Induced Fibrosis Treatment Market

Company	Therapeutic Pipeline	Clinical Evidence	Oncology Distribution	Geographic Reach
Merck KGaA	High	Strong	Strong	Global
Sanofi S.A.	High	Strong	Strong	Global
Bristol-Myers Squibb	High	Strong	Strong	Global
Galecto, Inc.	Medium	Moderate	Moderate	Regional
Trevi Therapeutics, Inc.	Medium	Moderate	Moderate	Regional

Source: Future Market Insights competitive analysis, 2026.

Key Players in the Radiation-Induced Fibrosis Treatment Market

Major Global Players

• Merck KGaA
• Sanofi S.A.
• Bristol-Myers Squibb
• Galecto, Inc.
• Trevi Therapeutics, Inc.

Emerging Players/Startups

• Galecto, Inc.
• Trevi Therapeutics, Inc.

Report Scope and Coverage

Quantitative Units	USD 83.9 million to USD 153.1 million, at a CAGR of 6.2%
Market Definition	The radiation-induced fibrosis treatment market encompasses products categorized by product, Therapy type, Route of administration, application, end user, distribution channel, technology across all major end-use applications.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, South Korea, Japan, UK, EU, 30 plus countries
Key Companies Profiled	Merck KGaA, Sanofi S.A., Bristol-Myers Squibb, Galecto, Inc., Trevi Therapeutics, Inc.
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, Projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Radiation-Induced Fibrosis Treatment Market Segmented by Product:

• Pharmaceuticals
  • Anti Fibrotic Drugs
    • Pirfenidone Based Therapy
    • Nintedanib Based Therapy
• Corticosteroids
  • • Oral Steroid Therapy
    • Injectable Steroid Therapy
• NSAIDs
  • • Pain Management
    • Inflammation Control
• Vitamin Based Therapy
  • Tocopherol Based Treatment
    • Antioxidant Therapy
• Combination Drug Therapy
  • Dual Mechanism Treatment
    • Symptom Management

Radiation-Induced Fibrosis Treatment Market Segmented by Therapy Type:

• Hyperbaric Oxygen Therapy
  • Systemic Oxygen Treatment
    • Tissue Oxygenation
    • Wound Healing Support
• Physiotherapy
  • Mobility Restoration
    • Fibrosis Management Exercises
    • Manual Therapy
• Microcurrent Stimulation
  • Electrical Stimulation Therapy
    • Tissue Repair Support
    • Pain Reduction Therapy
• Immunotherapy
  • Biologic Modulation
    • Immune Pathway Targeting
    • Anti Fibrotic Response

Radiation-Induced Fibrosis Treatment Market Segmented by Route of Administration:

• Oral
  • Tablet Based Therapy
    • Long Term Treatment
• Injectable
  • Intravenous Therapy
    • Hospital Based Care
• Topical
  • Skin Applied Treatment
    • Localized Fibrosis Care

Radiation-Induced Fibrosis Treatment Market Segmented by Application:

• Pulmonary Fibrosis
  • Lung Tissue Fibrosis
    • Post Radiation Lung Damage
• Breast Cancer Fibrosis
  • Post Treatment Complications
    • Radiation Side Effects
• Head And Neck Fibrosis
  • Tissue Hardening
    • Swallowing Dysfunction
• Pelvic Fibrosis
  • Organ Tissue Damage
    • Post Radiation Complications
• Dermal Fibrosis
  • Skin Tissue Fibrosis
    • Radiation Burns

Radiation-Induced Fibrosis Treatment Market Segmented by End User:

• Hospitals
  • Oncology Departments
    • Radiation Therapy Units
• Cancer Treatment Centers
  • Specialty Oncology Clinics
    • Advanced Care Facilities
• Ambulatory Surgical Centers
  • Outpatient Treatment
    • Minor Procedures
• Rehabilitation Centers
  • Physical Therapy Units
    • Long Term Recovery Care
• Research Institutes
  • Clinical Studies
    • Drug Development

Radiation-Induced Fibrosis Treatment Market Segmented by Distribution Channel:

• Hospital Pharmacies
  • Institutional Supply
    • Oncology Drug Dispensing
• Retail Pharmacies
  • Community Pharmacies
    • Prescription Drugs
• Online Pharmacies
  • Digital Distribution
    • Direct To Patient

Radiation-Induced Fibrosis Treatment Market Segmented by Technology:

• Drug Based Therapy
  • Conventional Pharmacology
    • Anti Fibrotic Agents
• Biologic Therapy
  • Monoclonal Antibodies
    • Immune Modulation
• Device Based Therapy
  • Oxygen Therapy Devices
    • Microcurrent Devices
• Regenerative Therapy
  • Tissue Repair Technologies
    • Stem Cell Based Approaches

Radiation-Induced Fibrosis Treatment Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• World Health Organization. (2025). Global Cancer Survivorship and Late Effects Report. WHO.
• National Cancer Institute. (2024). Cancer Treatment Side Effects and Survivorship Care Report. NCI.
• European Society for Radiotherapy and Oncology. (2025). Radiation-Induced Late Effects and Treatment Standards. ESTRO.
• United States Food and Drug Administration. (2025). Oncology Drug Approval and Post-Market Surveillance Report. FDA.
• International Agency for Research on Cancer. (2024). Global Cancer Statistics and Treatment Outcomes Report. IARC.

This bibliography is provided for reader reference.

This Report Answers

• Estimating the size of the radiation-induced fibrosis treatment market and revenue projections from 2026 to 2036.
• Segmentation by product, Therapy type, Route of administration, application, end user, distribution channel, technology.
• Insights across more than 30 country and regional markets.
• Analysis of key growth drivers, Restraints, and emerging opportunities.
• Assessment of the competitive landscape and strategic positioning.
• Identification of investment opportunities across primary application segments.
• Supply chain structure and distribution channel analysis.
• Delivery of data in PDF and Excel formats.